Inflammation

, Volume 40, Issue 5, pp 1599–1605 | Cite as

Andrographolide Benefits Rheumatoid Arthritis via Inhibiting MAPK Pathways

  • Zun-zhong Li
  • Ju-peng Tan
  • Li-li Wang
  • Qing-hua Li
ORIGINAL ARTICLE
First Online:

Abstract

Andrographolide (AD) is the main compound distributed in medicinal herb Andrographis paniculata and exhibits anti-inflammatory activity. AD has been used for the treatment of multiple inflammatory diseases. However, the therapeutic value of AD on human rheumatoid arthritis (RA) remains unclear. In this study, we investigated the effects of AD on collagen-induced arthritis (CIA) and human RA synovial fibroblasts (RA-SFs). CIA mice were treated with AD (dissolved in 0.5% CMC-Na, 100 mg/kg per day) or vehicle (0.5% CMC-Na) daily by oral gavage for 2 weeks. The arthritis severity and joint destruction were assessed. Serum anti-collagen II antibody (anti-CII Abs) and cytokines were determined by ELISA. TNFα-stimulated human RA-SFs were treated with varying doses of AD for in vitro investigation. Results showed that AD significantly attenuated the arthritis severity and joint damage. AD treatment significantly reduced the production of serum anti-CII, TNFα, IL-1β, and IL-6. In vitro, AD decreased the secretion of IL-1β and IL-6 from TNFα-stimulated RA-SFs in a dose-dependent manner. AD treatment reduced the TNFα-induced phosphorylation of p38 MAPK and ERK1/2 in a dose-dependent manner. Thus, our findings suggest that AD confers protective effects on autoimmune arthritis through inhibiting MAPK pathways.

KEY WORDS

andrographolide collagen-induced arthritis rheumatoid arthritis synovial fibroblasts 
This is a preview of subscription content, log in to check access.

Notes

Compliance with Ethical Standards

The study was approved by the Animal Care and Use Committee Women and Children’s Hospital of Linyi City. Synovial tissue samples were obtained from 20 patients with RA during orthopedic surgery after written informed consent. This study was approved by the Institutional Review Board of Women and Children’s Hospital of Linyi City.

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

10753_2017_600_MOESM1_ESM.xlsx (11 kb)
Figure 1A (XLSX 11 kb)
10753_2017_600_MOESM2_ESM.xlsx (10 kb)
Figure 1B (XLSX 9 kb)
10753_2017_600_MOESM3_ESM.xlsx (10 kb)
Figure 2B (XLSX 9 kb)
10753_2017_600_MOESM4_ESM.xlsx (10 kb)
Figure 3A (XLSX 9 kb)
10753_2017_600_MOESM5_ESM.xlsx (10 kb)
Figure 3B (XLSX 10 kb)
10753_2017_600_MOESM6_ESM.xlsx (10 kb)
Figure 4 (XLSX 9 kb)
10753_2017_600_MOESM7_ESM.xlsx (10 kb)
Figure 5A (XLSX 10 kb)
10753_2017_600_MOESM8_ESM.xlsx (10 kb)
Figure 5B (XLSX 10 kb)
10753_2017_600_MOESM9_ESM.xlsx (10 kb)
Figure 6A (XLSX 10 kb)
10753_2017_600_MOESM10_ESM.xlsx (10 kb)
Figure 6B (XLSX 10 kb)

References

  1. 1.
    Smolen, J.S., D. Aletaha, and I.B. McInnes. 2016. Rheumatoid arthritis. Lancet 388 (10055): 2023–2038.CrossRefPubMedGoogle Scholar
  2. 2.
    Filer, A. 2013. The fibroblast as a therapeutic target in rheumatoid arthritis. Current Opinion in Pharmacology 13 (3): 413–419.CrossRefPubMedGoogle Scholar
  3. 3.
    Turner, J.D., and A. Filer. 2015. The role of the synovial fibroblast in rheumatoid arthritis pathogenesis. Current Opinion in Rheumatology 27 (2): 175–182.CrossRefPubMedGoogle Scholar
  4. 4.
    Chandrasekaran, C.V., B. Murali, M. Deepak, and A. Agarwal. 2012. In vitro comparative evaluation of non-leaves and leaves extracts of Andrographis paniculata on modulation of inflammatory mediators. Antiinflamm Antiallergy Agents Med Chem. 11 (2): 191–197.CrossRefPubMedGoogle Scholar
  5. 5.
    Ren, J., Z. Liu, Q. Wang, J. Giles, J. Greenberg, N. Sheibani, K.C. Kent, and B. Liu. 2016. Andrographolide ameliorates abdominal aortic aneurysm progression by inhibiting inflammatory cell infiltration through downregulation of cytokine and integrin expression. The Journal of Pharmacology and Experimental Therapeutics 356 (1): 137–147.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Peng, S., N. Hang, W. Liu, W. Guo, C. Jiang, X. Yang, Q. Xu, and Y. Sun. 2016. Andrographolide sulfonate ameliorates lipopolysaccharide-induced acute lung injury in mice by down-regulating MAPK and NF-κB pathways. Acta Pharmaceutica Sinica B 6 (3): 205–211.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Shen, Y.C., C.F. Chen, and W.F. Chiou. 2002. Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. British Journal of Pharmacology 135 (2): 399–406.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Brand, D.D., K.A. Latham, and E.F. Rosloniec. 2007. Collagen-induced arthritis. Nature Protocols 2: 1269–1275.CrossRefPubMedGoogle Scholar
  9. 9.
    Li, J., C. Zhang, H. Jiang, and J. Cheng. 2015. Andrographolide inhibits hypoxia-inducible factor-1 through phosphatidylinositol 3-kinase/AKT pathway and suppresses breast cancer growth. Onco Targets Ther. 8: 427–435.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ding, L., J. Li, B. Song, X. Xiao, W. Huang, B. Zhang, X. Tang, M. Qi, Q. Yang, Q. Yang, L. Yang, and Z. Wang. 2014. Andrographolide prevents high-fat diet-induced obesity in C57BL/6 mice by suppressing the sterol regulatory element-binding protein pathway. The Journal of Pharmacology and Experimental Therapeutics 351 (2): 474–483.CrossRefPubMedGoogle Scholar
  11. 11.
    Viatte, S., J.C. Lee, B. Fu, M. Espéli, M. Lunt, J.N. De Wolf, L. Wheeler, J.A. Reynolds, M. Castelino, D.P. Symmons, P.A. Lyons, A. Barton, and K.G. Smith. 2016. Association between genetic variation in FOXO3 and reductions in inflammation and disease activity in inflammatory polyarthritis. Arthritis & Rhematology 68 (11): 2629–2636.CrossRefGoogle Scholar
  12. 12.
    Peng, J.S., S.Y. Chen, C.L. Wu, H.E. Chong, Y.C. Ding, A.L. Shiau, and C.R. Wang. 2016. Amelioration of experimental autoimmune arthritis through targeting of synovial fibroblasts by intraarticular delivery of MicroRNAs 140-3p and 140-5p. Arthritis & Rhematology 68 (2): 370–381.CrossRefGoogle Scholar
  13. 13.
    Moon, S.J., M.A. Lim, J.S. Park, J.K. Byun, S.M. Kim, M.K. Park, E.K. Kim, Y.M. Moon, J.K. Min, S.M. Ahn, S.H. Park, and M.L. Cho. 2014. Dual-specificity phosphatase 5 attenuates autoimmune arthritis in mice via reciprocal regulation of the Th17/Treg cell balance and inhibition of osteoclastogenesis. Arthritis & Rhematology 66 (11): 3083–3095.CrossRefGoogle Scholar
  14. 14.
    Rosloniec, E. F., Cremer, M., Kang, A., Myers, L. K. 2001 Collagen-induced arthritis. Curr Protoc Immunol;Chapter 15:Unit 15.51–25.Google Scholar
  15. 15.
    Aletaha, D., T. Neogi, A.J. Silman, J. Funovits, D.T. Felson, C.O. Bingham 3rd, N.S. Birnbaum, G.R. Burmester, V.P. Bykerk, M.D. Cohen, B. Combe, K.H. Costenbader, M. Dougados, P. Emery, G. Ferraccioli, J.M. Hazes, K. Hobbs, T.W. Huizinga, A. Kavanaugh, J. Kay, T.K. Kvien, T. Laing, P. Mease, H.A. Ménard, L.W. Moreland, R.L. Naden, T. Pincus, J.S. Smolen, E. Stanislawska-Biernat, D. Symmons, P.P. Tak, K.S. Upchurch, J. Vencovský, F. Wolfe, and G. Hawker. 2010. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism 62 (9): 2569–2581.CrossRefPubMedGoogle Scholar
  16. 16.
    Kono, M., S. Yasuda, R.L. Stevens, H. Koide, T. Kurita, Y. Shimizu, Y. Kanetsuka, K. Oku, T. Bohgaki, O. Amengual, T. Horita, T. Shimizu, T. Majima, T. Koike, and T. Atsumi. 2015. Ras guanine nucleotide-releasing protein 4 is aberrantly expressed in the synovial fibroblasts of patients with rheumatoid arthritis and controls their proliferation. Arthritis & Rhematology 67: 396–407.CrossRefGoogle Scholar
  17. 17.
    Izquierdo, E., J.D. Cañete, R. Celis, M.J. Del Rey, A. Usategui, S. Marsal, R. Sanmartí, G. Criado, and J.L. Pablos. 2011. Synovial fibroblast hyperplasia in rheumatoid arthritis: clinicopathologic correlations and partial reversal by anti–tumor necrosis factor therapy. Arthritis and Rheumatism 63: 2575–2583.CrossRefPubMedGoogle Scholar
  18. 18.
    Lowin, T., and R.H. Straub. 2015. Synovial fibroblasts integrate inflammatory and neuroendocrine stimuli to drive rheumatoid arthritis. Expert Review of Clinical Immunology 11 (10): 1069–1071.CrossRefPubMedGoogle Scholar
  19. 19.
    Wu, C., S. Wang, P. Xian, L. Yang, Y. Chen, and X. Mo. 2016. Effect of anti-TNF antibodies on clinical response in rheumatoid arthritis patients: a meta-analysis. BioMed Research International 2016: 7185708.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Müller-Ladner, U., T. Pap, R.E. Gay, M. Neidhart, and S. Gay. 2005. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nature Clinical Practice. Rheumatology 1 (2): 102–110.CrossRefPubMedGoogle Scholar
  21. 21.
    Volin, M.V., N. Huynh, K. Klosowska, K.K. Chong, and J.M. Woods. 2007. Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis and Rheumatism 56 (8): 2512–2522.CrossRefPubMedGoogle Scholar
  22. 22.
    Huang, C., K. Jacobson, and M.D. Schaller. 2004. MAP kinases and cell migration. Journal of Cell Science 117 (Pt 20): 4619–4628.CrossRefPubMedGoogle Scholar
  23. 23.
    Arthur, J.S., and S.C. Ley. 2013. Mitogen-activated protein kinases in innate immunity. Nature Reviews. Immunology 13 (9): 679–692.CrossRefPubMedGoogle Scholar
  24. 24.
    Ralph, J.A., and E.F. Morand. 2008. MAPK phosphatases as novel targets for rheumatoid arthritis. Expert Opinion on Therapeutic Targets 12 (7): 795–808.CrossRefPubMedGoogle Scholar
  25. 25.
    Ohori, M.E.R.K. 2008. Inhibitors as a potential new therapy for rheumatoid arthritis. Drug News & Perspectives 21 (5): 245–250.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Zun-zhong Li
    • 1
  • Ju-peng Tan
    • 2
  • Li-li Wang
    • 3
  • Qing-hua Li
    • 4
  1. 1.Department of Rheumatology and ImmunologyLinyi People’s HospitalLinyiChina
  2. 2.Department of Rheumatology and ImmunologyYidu Central HospitalWeifangChina
  3. 3.Clinical LaboratoryQingzhou Maternal and Child Health HospitalWeifangChina
  4. 4.Department of PediatricsWomen and Children’s Hospital of Linyi CityLinyiChina

Personalised recommendations